SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel
SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study.
Stay updated with breaking news from Solascure Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study.
29.08.2022 BRAIN Biotech AG: On Track to Reach Financial Year 2021/22 Targets, 9M Reporting | BRAIN Biotech AG | News | Nachricht | Mitteilung
DGAP-News: BRAIN Biotech AG / Key word(s): Quarter Results/Quarterly / Interim Statement BRAIN Biotech AG: On Track to Reach Financia...
DGAP-News: BRAIN Biotech AG / Key word: Half Year Results/Half Year Report BRAIN Biotech AG: Ongoing Dynamic Sales Development and Rising Profitability, 6M Reporting 30.05.2022 /... | May 30, 2022
DGAP-News: BRAIN Biotech AG / Key word(s): Half Year Results/Half Year Report BRAIN Biotech AG: Ongoing Dynamic Sales Development and...